Latest Breaking News On - Institut de rhumatologie - Page 1 : comparemela.com

- Approval is based on results from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which RINVOQ delivered rapid and meaningful disease control, meeting the primary endpoint of ASAS40 response at. | May 9, 2023

Denis choquetteTracey ramsayCanadian spondylitis associationCanadian spondyloarthritis associationHealth canadaAbbvie corporationJanus kinaseInstitut de rhumatologieScientific directorSpondyloarthritis associationVice presidentGeneral managerAllergan aestheticsAnn rheumUnderstanding axial spondyloarthritisProgression from non radiographic